ETFs Extend Buying Streak with $38 Million in Amgen Shares

On October 1, 2026, exchange-traded funds (ETFs) accumulated $38.0 million in Amgen (AMGN) shares, marking the fifth consecutive day of net purchases. This latest buying spree involved 49 ETFs acquiring shares while 25 reduced their holdings. The net inflows for the previous four days ranged from $1.4 million on September 30 to a peak of $258.0 million on September 28, indicating sustained interest in the healthcare stock.

The largest ETF buyers by dollar value were DIA, QQQ, and SPYM, investing $60.4 million, $12.6 million, and $7.2 million respectively. DIA was the most significant buyer, adding 148,350 shares worth $60.4 million, increasing its stake by 2.91% to a total of 5,247,310 shares, which represents 4.75% of the fund. Other ETFs contributing to the buying activity included XLV, UDOW, DGRO, IYH, and QQQM.

Amgen, a leading biotechnology company, reported trailing-12-month revenue of $38.20 billion, reflecting a 9.5% year-over-year increase. The company's gross margin stands at 72.7%, with a net margin of 22.9%. The stock trades at a P/E of 25.04, P/B of 18.64, and P/S of 5.71. Amgen's GF Score is 85, and its GF Value of $367.83 is lower than its current price of $403.04. The dividend yield is 2.46%, and the shares have returned 25.66% year to date.

Investors will be watching to see if Amgen can maintain this streak of net ETF buying, which has varied significantly in daily value. The company's strong financial performance and consistent ETF inflows highlight its attractiveness in the healthcare sector.